Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy.
BACKGROUND
Phagocytosis of apoptotic cells by macrophages induces a suppressor phenotype. Previous data from our group suggested that this occurs via Platelet-activating factor receptor (PAF-R)-mediated pathways. In the present study, we investigated the impact of apoptotic cell inoculation or induction by a chemotherapeutic agent (dacarbazine, DTIC) on tumour growth, microenvironmental parameters and survival, and the effect of treatment with a PAF-R antagonist (WEB2170). These studies were performed in murine tumours: Ehrlich Ascitis Tumour (EAT) and B16F10 melanoma.


METHODS
Tumour growth was assessed by direct counting of EAT cells in the ascitis or by measuring the volume of the solid tumour. Parameters of the tumour microenvironment, such as the frequency of cells expressing cyclo-oxygenase-2 (COX-2), caspase-3 and galectin-3, and microvascular density, were determined by immunohistochemistry. Levels of vascular endothelium growth factor (VEGF) and prostaglandin E2 (PGE2) were determined by ELISA, and levels of nitric oxide (NO) by Griess reaction. PAF-R expression was analysed by immunohistochemistry and flow cytometry.


RESULTS
Inoculation of apoptotic cells before EAT implantation stimulated tumour growth. This effect was reversed by in vivo pre-treatment with WEB2170. This treatment also reduced tumour growth and modified the microenvironment by reducing PGE2, VEGF and NO production. In B16F10 melanoma, WEB2170 alone or in association with DTIC significantly reduced tumour volume. Survival of the tumour-bearing mice was not affected by WEB2170 treatment but was significantly improved by the combination of DTIC with WEB2170. Tumour microenvironment elements were among the targets of the combination therapy since the relative frequency of COX-2 and galectin-3 positive cells and the microvascular density within the tumour mass were significantly reduced by treatment with WEB2170 or DTIC alone or in combination. Antibodies to PAF-R stained the cells from inside the tumour, but not the tumour cells grown in vitro. At the tissue level, a few cells (probably macrophages) stained positively with antibodies to PAF-R.


CONCLUSIONS
We suggest that PAF-R-dependent pathways are activated during experimental tumour growth, modifying the microenvironment and the phenotype of the tumour macrophages in such a way as to favour tumour growth. Combination therapy with a PAF-R antagonist and a chemotherapeutic drug may represent a new and promising strategy for the treatment of some tumours.
de Oliveira
Soraya I
SI
Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil. sojancar@icb.usp.br.
Andrade
Luciana N S
LN
Onuchic
Ana C
AC
Nonogaki
Sueli
S
Fernandes
Patrícia D
PD
Pinheiro
Mônica C
MC
Rohde
Ciro B S
CB
Chammas
Roger
R
Jancar
Sonia
S
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001381:Azepines / Q000008:administration & dosage; D002286:Carcinoma, Ehrlich Tumor / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D053148:Caspase 3 / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000378:metabolism; D003606:Dacarbazine / Q000008:administration & dosage; D015232:Dinoprostone / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D037502:Galectin 3 / Q000378:metabolism; D007150:Immunohistochemistry; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000517:prevention & control; D009569:Nitric Oxide / Q000378:metabolism; D010641:Phenotype; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D013997:Time Factors; D014230:Triazoles / Q000008:administration & dosage; D047368:Tumor Burden; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D018906:Antineoplastic Agents, Alkylating; D001381:Azepines; D037502:Galectin 3; D010980:Platelet Membrane Glycoproteins; D043562:Receptors, G-Protein-Coupled; D014230:Triazoles; D042461:Vascular Endothelial Growth Factor A; C039351:platelet activating factor receptor; C467480:vascular endothelial growth factor A, mouse; D009569:Nitric Oxide; D003606:Dacarbazine; C063964:bepafant; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; C505409:Casp3 protein, mouse; D053148:Caspase 3; D015232:Dinoprostone
Int J Cancer. 2005 Apr 10;114(3):356-63
15573371
Am J Pathol. 2000 Nov;157(5):1713-25
11073830
Clin Cancer Res. 2003 Sep 15;9(11):4214-20
14519648
J Biochem. 2002 Jun;131(6):773-9
12038971
Glycobiology. 2009 Jan;19(1):16-20
18849325
J Exp Clin Cancer Res. 2004 Dec;23(4):681-90
15743040
J Immunol. 2008 Feb 15;180(4):2650-8
18250477
FASEB J. 2007 Oct;21(12):3153-61
17513560
J Clin Invest. 2001 Oct;108(7):957-62
11581295
Food Chem Toxicol. 1984 Jul;22(7):541-3
6378739
FEBS Lett. 2006 May 29;580(13):3006-12
16684540
Annu Rev Biochem. 2000;69:419-45
10966465
Naunyn Schmiedebergs Arch Pharmacol. 1987 Mar;335(3):351-5
3587377
Nat Rev Cancer. 2004 Jan;4(1):71-8
14708027
J Invest Dermatol. 2009 Mar;129(3):573-83
18843294
Lab Invest. 2008 Aug;88(8):896-906
18542048
J Clin Invest. 1998 Feb 15;101(4):890-8
9466984
Cancer Res. 1996 Jun 1;56(11):2662-5
8653713
Immunity. 2005 Oct;23(4):344-6
16226499
Cancer Res. 2006 May 1;66(9):4681-6
16651419
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
17895480
Prostaglandins Other Lipid Mediat. 2006 Jul;80(1-2):62-73
16846787
Clin Cancer Res. 2009 Aug 1;15(15):4867-74
19622578
Gene Ther. 2003 Nov;10(23):1992-7
14528323
Nat Rev Cancer. 2005 Jul;5(7):516-25
15965493
Inflammation. 1990 Feb;14(1):125-32
2323805
Nat Rev Immunol. 2005 Dec;5(12):953-64
16322748
Crit Care Med. 2002 May;30(5 Suppl):S294-301
12004251
Int J Immunopharmacol. 1990;12(1):57-65
2303318
Melanoma Res. 2001 Jun;11(3):247-53
11468513